Search
Rimtuzalcap
go.drugbank.com/drugs/DB16733InvestigationalRimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.[L38414]
Synonyms: N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amineGEM-231
go.drugbank.com/drugs/DB05798InvestigationalA monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.
Chromium Cr-51
go.drugbank.com/drugs/DB11140ApprovedInvestigationalIt is used as a diagnostic radiopharmaceutical agent in nephrology to determine glomerular filtration rate,[A249765,A249770] and in hematology to determine red blood cell volume or mass, study the red … Chromium Cr-51 is an isotope of chromium that has been used as a radioactive label for decades.
Hymecromone
go.drugbank.com/drugs/DB07118InvestigationalCategories: Compounds used in a research, industrial, or household settingChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class.
Clevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalA compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
Mixtures: Canesten Bifonazol comp. - Salbe + NagelsetProducts: EUREA CREAMTifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalTifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.